Inflammatory Bowel Disease

Adverse pregnancy outcomes among women with inflammatory bowel disease on biologic therapy were comparable to that of the general population, according to study results.

Additional, extended treatment with mirikizumab helped produce a clinical response in patients with ulcerative colitis who initially did not respond to treatment, according to study results.

Data from six phase 2/3 studies showed that Stelara had a favorable safety profile through 1-year of treatment in Crohn’s disease and ulcerative colitis, according to research published in Inflammatory Bowel Diseases.

Long-term data from the GEMINI trial showed that Entyvio maintained its favorable safety profile in patients with inflammatory bowel disease over 8 years. It was the top story in gastroenterology last week.

Patients who received Entyvio or Stelara for inflammatory bowel disease who had more comorbidities were at increased risk for hospitalization and infection, according to research published in Alimentary Pharmacology & Therapeutics.

Remicade plus optimized thiopurine was superior in patients with Crohn’s disease compared with infliximab monotherapy for response initiation, durability and clinical outcomes in the first 6 months after induction, according to recently published study results.

The safety profile of Entyvio remained favorable through 8 years of use in patients with inflammatory bowel disease, according to results from the GEMINI long-term safety study.

ABX464, a once-daily, oral treatment for ulcerative colitis, showed efficacy for up to 2 years of therapy in a phase 2a trial, according to the drug’s manufacturer Abivax.

Higher cumulative exposure to systemic antibiotic therapy was associated with an increased risk for inflammatory bowel disease, according to a recent study. It was the top story in gastroenterology last week.

Achievement of histo-endoscopic mucosal healing after induction therapy of Stelara in patients with ulcerative colitis correlated with lower disease activity at the end of maintenance therapy compared with histologic or endoscopic improvement alone, according to results published in Gastroenterology.